Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

Clinical trial NCT05132985 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05132985
Sponsor: Liaoning Cancer Hospital & Institute
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC EGF-R Positive Non-Small Cell Lung Cancer

Start date: 2022-01-01
Primary completion: 2024-07-01
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.